

Pharmacy Formulary Updates Effective February 1, 2021

The MVP Health Care® (MVP) Pharmacy & Therapeutics (P&T) Committee has determined that the following drugs, which have been recently approved by the FDA, will require prior authorization for at least the first six months following the date they are available on the market. The most current versions of our Formularies and Prior Authorization forms are available at mvphealthcare.com.

New Drugs (prior authorization required)

Drug Name	Indication	Commercial & Marketplace Tier	Medicare Part D Tier	MVP Medicaid
Conjupri	Hypertension	Tier 3	Non-Formulary	Non-Formulary
Xywav	Narcolepsy	Tier 3	Non-Formulary	Non-Formulary
Alkindi Sprinkle	Adrenocortical Insufficiency	Tier 3	Non-Formulary	Non-Formulary

For Commercial & Exchange (non-Medicare) business:

New generic formulary additions	
Drug Name	Tier
deferiprone (Ferriprox)	Tier 1 (Tier 2 Exchange)
sapropterin powder (Kuvan)	Tier 1 with PA (Tier 2 with PA for Exchange)
lapatinib (Tykerb)	Tier 1 (Tier 2 Exchange)
efavirenz / emtricitabine / tenofovir (Atripla)	Tier 1 (Tier 2 Exchange) Brand is Tier 2
fosfomycin powder pack (Monurol Granules)	Tier 1 (Tier 2 Exchange)
emtricitabine / tenofovir (Truvada)	Tier 1 (Tier 2 Exchange)
methylphenidate ER (Aptensio XR)	Tier 1 (Tier 2 Exchange)
tavaborole solution (Kerydin)	Tier 1 with PA (Tier 2 with PA for Exchange)

All brands will be non-formulary, Tier 3

January 1, 2021 Changes

Medicaid Business:

- **Truvada:** Generic Truvada has been added to tier 1. Brand Truvada will remain at tier 2.
- **NDC Labeler Alignment**

MVP will make formulary changes to our Medicaid line of business. Drugs manufactured or distributed by labelers who have not signed a drug rebate agreement with the federal Department of Health and Human Services (DHHS) are excluded from coverage through MVP. Claims that reject for this reason should be filled using an alternative NDC or product that is included in the Medicaid Drug Rebate Program.

April 2, 2021 Change

- **Suboxone Change Delayed**

The Department of Health had previously advised of the requirement for brand Suboxone films to be placed on tier 1. This change has been delayed until April 1, 2021.

February 1, 2021 Change

Commercial and Exchange Business:

- Brands Zytiga & Truvada will be excluded since the generics are now available.

To view all communications, visit mvphealthcare.com/FastFax

To receive future FastFax messages by email, send a request to your PR Representative.

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

